Table 2 Associations between mtDNA copy number and clinicopathological characteristics in BC patients
From: High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients
Characteristics | Quintile 1(n = 132) | Quintile 2–5(n = 529) | P-value |
|---|---|---|---|
Age at diagnosis | Â | Â | 0.753 |
 ≤ 40 | 43 (32.6%) | 164 (31.0%) |  |
 >40 | 89 (67.4%) | 365 (69.0%) |  |
Tumor size(cm) | Â | Â | 0.348 |
 ≤ 2 | 47 (35.6%) | 164 (31.0%) |  |
 >2 | 85 (64.4%) | 365 (69.0%) |  |
Nodal status | Â | Â | 0.272 |
 Negative | 45 (34.1%) | 210 (39.7%) |  |
 Positive | 87 (65.9%) | 319 (60.3%) |  |
Clinical stage | Â | Â | 0.622 |
 I | 23 (17.4%) | 104 (19.7%) |  |
 II + III | 109 (82.6%) | 425 (80.3%) |  |
Grade | Â | Â | 0.041 |
 I + II | 109 (82.6%) | 391 (73.9%) |  |
 III | 23 (17.4%) | 138 (26.1%) |  |
HR | Â | Â | 0.186 |
 Negative | 40 (30.3%) | 195 (36.9%) |  |
 Positive | 92 (69.7%) | 334 (63.1%) |  |
HER2 | Â | Â | 0.749 |
 Negative | 95 (72.0%) | 372 (70.3%) |  |
 Positive | 37 (28.0%) | 157 (29.7%) |  |
Subtype | Â | Â | 0.393 |
 Luminal A | 28 (21.2%) | 95 (18.0%) |  |
 Luminal B | 64 (48.4%) | 239 (45.2%) |  |
 HER2+ | 20 (15.2%) | 81 (15.3%) |  |
 Triple-negative | 20 (15.2%) | 114 (21.5%) |  |